Biogen (BIIB) Other Accumulated Expenses (2009 - 2026)

Biogen's Other Accumulated Expenses history runs 18 years deep, the most recent figure standing at $2.6 billion for Q2 2026.

• In Q2 2026, Other Accumulated Expenses fell 1.29% year-over-year to $2.6 billion; the TTM figure through Jun 2026 stood at $2.6 billion (down 1.29% YoY), while the FY2025 annual figure was $2.8 billion, changed 0.18% from the prior year.
• Other Accumulated Expenses for Q2 2026 stood at $2.6 billion, up from $2.5 billion in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.8 billion in Q3 2023, with the low at $2.2 billion in Q1 2022.
• The 5-year median for Other Accumulated Expenses is $2.6 billion (2023), against an average of $2.7 billion.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses rose 29.61% in 2022, then dropped 28.22% in 2024.
• Biogen's Other Accumulated Expenses stood at $2.5 billion in 2022, then climbed by 4.05% to $2.6 billion in 2023, then advanced by 7.02% to $2.8 billion in 2024, then declined by 0.18% to $2.8 billion in 2025, then slipped by 6.29% to $2.6 billion in 2026.
• Business Quant data shows BIIB's Other Accumulated Expenses at $2.6 billion in Q2 2026, $2.5 billion in Q1 2026, and $2.8 billion in Q4 2025.